Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed No phase listed Observational

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

ClinicalTrials.gov ID: NCT05388474

Public ClinicalTrials.gov record NCT05388474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 2:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab in a Real-World Setting: United States

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The virological efficacy of ibalizumab has been clearly demonstrated in multiple clinical trials. This study will expand ibalizumab's clinical data set and allow a better understanding of the virologic response durability on ARV regimens with or without ibalizumab in a heterogeneous real-world patient population. Additional data on the efficacy and safety of ibalizumab and its impact on patient reported outcomes will be captured until study end. Primary Objective: To evaluate the long-term efficacy, safety, and durability of ibalizumab in combination with other ARVs by comparing the virologic, immunologic and clinical outcomes of patients receiving ibalizumab treatment versus patients not receiving ibalizumab. Secondary Objective: To assess the efficacy of ibalizumab in combination with other antiretrovirals by comparing the virologic, immunologic, clinical and patient reported outcomes of patients before and after they receive ibalizumab treatment. To assess the long-term safety and tolerability of ibalizumab. Other Objectives: To assess risk factors/predictors of virologic and immunologic response. To assess efficacy and safety in special populations that enroll.

Study identification

NCT ID
NCT05388474
Recruitment status
Completed
Study type
Observational
Phase
Not listed
Lead sponsor
Theratechnologies
Industry
Enrollment
168 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 22, 2022 (Actual)
Primary completion
Jul 2, 2026 (Actual)
Completion
Jul 2, 2026 (Actual)
Last update posted
Jul 27, 2026

2022 – 2026

United States locations

U.S. sites
36
U.S. states
14
U.S. cities
25
Facility City State ZIP Site status
Ruane Clinical Research Los Angeles California 90036 —
Mills Clinical Research Los Angeles California 90046 —
BIOS Clinical Research Palm Springs California 92262 —
UC San Diego Owen Clinic San Diego California 92103 —
Yale University New Haven Connecticut 06520 —
Circle Care Center Stamford Connecticut 06850 —
Waterbury Hospital Waterbury Connecticut 06702 —
Whitman Walker Health Washington D.C. District of Columbia 20005 —
Georgetown University Medical Center Washington D.C. District of Columbia 20007 —
Aids Healthcare Foundation Fort Lauderdale Florida 33308 —
Gary J. Richmond, M.D., PA Fort Lauderdale Florida 33316 —
Midway Specialty Care Center Miami Beach Miami Beach Florida 33140 —
Orlando Immunology Center (OIC) Orlando Florida 32803 —
Bliss Health Orlando Florida 32806 —
Can Community Health Tampa Florida 33614 —
St-Joseph's Comprehensive Research Tampa Florida 33614 —
CAN Community Health Tampa Florida 34232 —
Triple O Research Institute PA West Palm Beach Florida 33407 —
Indiana University Health Inc. Bloomington Indiana 47405 —
University of Maryland School of Medicine Baltimore Maryland 21201 —
Boston Medical Center Boston Massachusetts 02118 —
The Research Institute Springfield Massachusetts 01105 —
Henry Ford Hospital Detroit Michigan 48202 —
Las Vegas Research Center Las Vegas Nevada 89106 —
I.D. Care Associates, PA Hillsborough New Jersey 08844 —
Prime Healthcare Services - St Michael's Medical Center Newark New Jersey 07102 —
SUNY Upstate Medical Center Syracuse New York 13210 —
Amity Medical Group Charlotte North Carolina 28215 —
The Roper St. Francis Ryan White Wellness Center Charleston South Carolina 29407 —
Medical University of South Carolina Charleston South Carolina 29425 —
Prism Health North Texas Dallas Texas 75204 —
North Texas Infectious Diseases Consultants, P.A Dallas Texas 75246 —
Therapeutic Concepts, PA Houston Texas 77004 —
UT Health Houston Houston Texas 77030 —
St. Hope Foundation Houston Texas 77036 —
Legacy Community Pharmacy Services Houston Texas 77074 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05388474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 27, 2026 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05388474 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →